MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.
Paclitaxel (Taxol) is an effective chemotherapeutic agent for treatment of cancer patients. Despite impressive initial clinical responses, the majority of patients eventually develop some degree of resistance to Taxol-based therapy. The mechanisms underlying cancer cells resistance to Taxol are not fully understood. MicroRNA (miRNA) has emerged to play important roles in tumorigenesis and drug resistance. However, the interaction between the development of Taxol resistance and miRNA has not been previously explored. In this study we utilized a miRNA array to compare the differentially expressed miRNAs in Taxol-resistant and their Taxol-sensitive parental cells. We verified that miR-125b, miR-221, miR-222, and miR-923 were up-regulated in Taxol-resistant cancer cells by real-time PCR. We further investigated the role and mechanisms of miR-125b in Taxol resistance. We found that miR-125b was up-regulated in Taxol-resistant cells, causing a marked inhibition of Taxol-induced cytotoxicity and apoptosis and a subsequent increase in the resistance to Taxol in cancer cells. Moreover, we demonstrated that the pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) is a direct target of miR-125b. Down-regulation of Bak1 suppressed Taxol-induced apoptosis and led to an increased resistance to Taxol. Restoring Bak1 expression by either miR-125b inhibitor or re-expression of Bak1 in miR-125b-overexpressing cells recovered Taxol sensitivity, overcoming miR-125-mediated Taxol resistance. Taken together, our data strongly support a central role for miR-125b in conferring Taxol resistance through the suppression of Bak1 expression. This finding has important implications in the development of targeted therapeutics for overcoming Taxol resistance in a number of different tumor histologies.
Zhou
Ming
M
Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36604, USA.
Liu
Zixing
Z
Zhao
Yuhua
Y
Ding
Yan
Y
Liu
Hao
H
Xi
Yaguang
Y
Xiong
Wei
W
Li
Guiyuan
G
Lu
Jianrong
J
Fodstad
Oystein
O
Riker
Adam I
AI
Tan
Ming
M
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D045744:Cell Line, Tumor; D002470:Cell Survival; D019008:Drug Resistance, Neoplasm; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism*; D020411:Oligonucleotide Array Sequence Analysis; D017239:Paclitaxel / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D050998:bcl-2 Homologous Antagonist-Killer Protein / Q000378:metabolism*
D000970:Antineoplastic Agents; C494772:BAK1 protein, human; C531888:MIRN125 microRNA, human; D035683:MicroRNAs; D019253:Proto-Oncogene Proteins c-bcl-2; D050998:bcl-2 Homologous Antagonist-Killer Protein; D017239:Paclitaxel
Biochem Biophys Res Commun. 2008 Dec 5;377(1):114-9
18834855
Adv Exp Med Biol. 2007;608:119-29
17993237
Clin Exp Metastasis. 1997 May;15(3):272-306
9174129
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19983-8
18056640
Int J Cancer. 2009 May 1;124(9):2236-42
19127597
Cancer Res. 2004 May 15;64(10):3479-85
15150101
Cancer Res. 2005 Aug 15;65(16):7065-70
16103053
EMBO J. 2007 Aug 8;26(15):3699-708
17627278
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9779-84
12902540
Gastroenterology. 2009 May;136(5):1689-700
19422085
J Biol Chem. 2007 Jan 12;282(2):1479-86
17110380
Nucleic Acids Res. 2010 Jun;38(10):3222-32
20144951
Cell Physiol Biochem. 2009;23(4-6):347-58
19471102
Int J Cancer. 2009 Jul 15;125(2):345-52
19378336
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1949-54
18238902
Nat Struct Mol Biol. 2009 Jan;16(1):23-9
19079265
Nature. 2000 Feb 24;403(6772):901-6
10706289
Mol Cell. 2002 May;9(5):993-1004
12049736
Clin Cancer Res. 2008 May 1;14(9):2690-5
18451233
Annu Rev Biochem. 1993;62:385-427
8102521
Genes Dev. 2009 Apr 1;23(7):862-76
19293287
Cancer Res. 2009 Feb 15;69(4):1279-83
19190326
Cancer Res. 2007 Sep 15;67(18):8699-707
17875710
Cell. 1994 Aug 26;78(4):539-42
8069905
J Biol Chem. 2008 Nov 7;283(45):31079-86
18790736
Clin Cancer Res. 2009 Feb 15;15(4):1326-34
19228734
J Biol Chem. 2007 Aug 10;282(32):23716-24
17569667
Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11358-62
7972064
Oncogene. 2008 Mar 13;27(12):1788-93
17891175
Cell. 2009 Aug 7;138(3):592-603
19665978
Gynecol Oncol. 1995 Feb;56(2):231-4
7534740
Dev Biol. 1999 Dec 15;216(2):671-80
10642801
Genes Dev. 2003 Dec 1;17(23):2922-32
14633975
Cancer Res. 2009 Jul 1;69(13):5292-3
19549886
Genes Chromosomes Cancer. 2009 Jul;48(7):569-82
19396866
PLoS Pathog. 2009 Dec;5(12):e1000681
19997496
Oncogene. 2009 Oct 22;28(42):3689-701
19668225
Cell Death Differ. 2002 Jun;9(6):636-42
12032672
Cancer Res. 2003 Mar 15;63(6):1207-13
12649178
J Biol Chem. 1999 Aug 13;274(33):22932-40
10438458
Mol Cancer. 2010 Feb 09;9:33
20144215
Oncogene. 2007 Nov 29;26(54):7590-5
17563749
Nat Cell Biol. 2008 Feb;10(2):202-10
18193036
JAMA. 2007 May 2;297(17):1901-8
17473300
Nat Med. 2008 Nov;14(11):1271-7
18931683
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11737-42
11562465
Oncogene. 2009 Jan 8;28(1):140-5
18836483
Gynecol Oncol. 2008 Dec;111(3):478-86
18823650
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5166-71
18362358
Cell. 2004 Jan 23;116(2):281-97
14744438
EMBO Rep. 2009 Apr;10(4):400-5
19247375
J Exp Med. 2008 Oct 27;205(11):2499-506
18936236
Nucleic Acids Res. 2006 Jan 23;34(2):e13
16432257
Nat Rev Cancer. 2006 Nov;6(11):857-66
17060945
Int J Cancer. 2009 Sep 15;125(6):1328-33
19437538
Cancer Chemother Pharmacol. 2007 Feb;59(2):235-49
16972069